4P020

4P020 is a small molecule drug developed by 4P-Pharma as a first-in-class beta-3 adrenergic receptor agonist. Its primary mechanism of action is the activation of the β3-adrenergic receptor, which is being explored for its therapeutic potential in rare ophthalmological diseases. The drug is under preclinical development for Stargardt disease and dry age-related macular degeneration (dry AMD), both of which are degenerative eye conditions with significant unmet medical need. Development involves collaboration with Institut de la Vision and SATT Lutech[2][6][1][4]. No approved indications or known adverse events have been reported to date.